Eli Lilly announced the success of the global health care company’s clinical trial on lebrikizumab as a treatment for people diagnosed with moderate to severe atopic dermatitis (AD). 

Eli Lilly is in the news for positive Olumiant data in Covid-19, a drop in Covid-19 product sales for second-quarter 2021, and a protest of one of the company’s ads.

Loxo Oncology, a division of Eli Lilly, and Kumquat Biosciences teamed up in a deal valued at more than $2 billion to discover and develop novel small molecules designed to stimulate tumor-specific immune responses in cancer patients.

The U.S. health regulator expanded the emergency use authorization for Eli Lilly’s baricitinib for Covid-19, saying the arthritis medicine could now be used without taking Gilead’s drug remdesivir along with the product.

Indianapolis-based Eli Lilly and Company is acquiring Pasadena, Calif.-based Protomer Technologies in a deal that may exceed $1 billion. 

Eli Lilly’s investigational diabetes drug tirzepatide is showing significant promise in targeting A1C levels and weight loss in patients with type 2 diabetes, including those who had never been previously treated for the disease. In other positive clinical results presented at the American Diabetes Association’s 81st Scientific Sessions meeting, Novo Nordisk data demonstrated an investigational 2mg dose of injectable Ozempic (semaglutide) generated statistically significant and superior reductions in A1C compared to a 1mg dose of Ozempic.

Eli Lilly will apply for U.S. health regulator’s accelerated approval during 2021 for the company’s experimental Alzheimer’s drug, weeks after Biogen Inc.’s controversial drug for the disease was approved.

Eli Lilly and Company announced the launch of a head-to-head study to compare once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant) for the prevention of migraine.

Across the pharmaceutical industry, forging collaborations are a key tool to bringing new medications through the clinic and to market. This week, multiple companies have partnered in attempts to bring forth new therapies. BioSpace took a look at some of these announcements.

Eli Lilly said on May 27 the company received a subpoena from the U.S. Department of Justice related to the New Jersey plant that makes the Covid-19 treatment, bamlanivimab.